Martin Evans
Chief Tech/Sci/R&D Officer presso ROQUEFORT THERAPEUTICS PLC
Profilo
Martin John Evans is the founder of Cell Therapy Ltd.
(founded in 2009) and Celixir Plc (founded in 2009).
He is currently the President & Chief Scientific Officer at Cell Therapy Ltd.
and the President, Chief Scientific Officer & Director at Celixir Plc.
Dr. Evans is also the founder of Oncogeni Ltd.
(founded in 2019) and currently serves as a Director there.
Additionally, he is currently the Chief Scientific Officer & Executive Director at Roquefort Therapeutics Plc (since 2022).
Dr. Evans previously held the position of President at the University of Cardiff.
He obtained his doctorate degree from University College London in 1969.
Posizioni attive di Martin Evans
| Società | Posizione | Inizio |
|---|---|---|
| ROQUEFORT THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 16/09/2022 |
Cell Therapy Ltd.
 Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Founder | 01/01/2009 |
Celixir Plc
 Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | Founder | 01/01/2009 |
Oncogeni Ltd.
 Oncogeni Ltd. BiotechnologyHealth Technology Part of Roquefort Therapeutics Plc, Oncogeni Ltd. operates as a British biotechnology company. The private company is based in Stratford-upon-Avon, UK. The company was founded in 2019 by Nobel Laureate, Martin John Evans, Trevor Ajan Reginald. Oncogeni was acquired by Roquefort Therapeutics Plc on September 16, 2022 for $4.61 million. | Founder | 01/05/2019 |
Precedenti posizioni note di Martin Evans
| Società | Posizione | Fine |
|---|---|---|
| University of Cardiff | President | - |
Formazione di Martin Evans
| University College London | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ROQUEFORT THERAPEUTICS PLC | Health Technology |
| Aziende private | 3 |
|---|---|
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Health Technology |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | Health Technology |
Oncogeni Ltd.
Oncogeni Ltd. BiotechnologyHealth Technology Part of Roquefort Therapeutics Plc, Oncogeni Ltd. operates as a British biotechnology company. The private company is based in Stratford-upon-Avon, UK. The company was founded in 2019 by Nobel Laureate, Martin John Evans, Trevor Ajan Reginald. Oncogeni was acquired by Roquefort Therapeutics Plc on September 16, 2022 for $4.61 million. | Health Technology |
- Borsa valori
- Insiders
- Martin Evans
